224 related articles for article (PubMed ID: 9705303)
1. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
2. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes.
Qiu Y; Fairbanks LD; Rückermann K; Hawrlowicz CM; Richards DF; Kirschbaum B; Simmonds HA
Transplantation; 2000 Mar; 69(5):890-7. PubMed ID: 10755546
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis.
Silva HT; Cao W; Shorthouse RA; Löffler M; Morris RE
Transplant Proc; 1997; 29(1-2):1292-3. PubMed ID: 9123312
[No Abstract] [Full Text] [Related]
7. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation.
Dimitrova P; Skapenko A; Herrmann ML; Schleyerbach R; Kalden JR; Schulze-Koops H
J Immunol; 2002 Sep; 169(6):3392-9. PubMed ID: 12218161
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous separation by high-performance liquid chromatography of carbamoyl aspartate, carbamoyl phosphate and dihydroorotic acid.
Fairbanks LD; Carrey EA; Rückemann K; Swaminathan R; Kirschbaum B; Simmonds HA
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):487-93. PubMed ID: 10517371
[TBL] [Abstract][Full Text] [Related]
10. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.
Fairbanks LD; Bofill M; Ruckemann K; Simmonds HA
J Biol Chem; 1995 Dec; 270(50):29682-9. PubMed ID: 8530356
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841
[No Abstract] [Full Text] [Related]
13. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
14. Uridylate-trapping sugar analogs in combination with inhibitors of uridylate synthesis de novo and 5-fluorouridine.
Keppler D; Fauler J; Gasser T; Holstege A; Leube K; Schulz-Holstege C; Weckbecker G
Adv Enzyme Regul; 1985; 23():61-79. PubMed ID: 2416194
[TBL] [Abstract][Full Text] [Related]
15. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of new immunosuppressants.
Halloran PF
Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide interferes with pyrimidine nucleotide biosynthesis.
Cherwinski HM; Byars N; Ballaron SJ; Nakano GM; Young JM; Ransom JT
Inflamm Res; 1995 Aug; 44(8):317-22. PubMed ID: 8581517
[TBL] [Abstract][Full Text] [Related]
20. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
Korn T; Magnus T; Toyka K; Jung S
J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
